Thrombotargets is an innovator in Drug Discovery and in Drug Development because thanks to its multiple internal therapeutic programs and proven proprietary platforms it helps significantly improving the speed and the efficiency of the research as well as driving the clinical trials to success.
Thrombotargets has developed and adapted to High Throughput Screening (HTS) a new family of biological assays named capable to quantify:
- Clot formation and clot lysis, simultaneously: HemostaBioplatformScreenTM
- Total antioxidant capacity: OxidantBioplatformScreenTM
- Low-density lipoprotein (LDL) modification: AtheroBioplatformScreenTM
Using its own HTS Platforms, Thrombotargets is continuously creating a novel and promising pipeline of drug candidates.